Advertisement

Topics

Roche Convinces UK NICE On Cost-Benefit Of RoActemra For Giant Cell Arteritis

19:14 EDT 13 Mar 2018 | Elsevier Business Intelligence

After an initial rejection, Roche's IL-6 drug RoActemra has received support from the UK's health technology assessme...

Original Article: Roche Convinces UK NICE On Cost-Benefit Of RoActemra For Giant Cell Arteritis

NEXT ARTICLE

More From BioPortfolio on "Roche Convinces UK NICE On Cost-Benefit Of RoActemra For Giant Cell Arteritis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...